GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and heterologous immunization approaches implemented worldwide for booster doses call for diversified vaccine portfolios. GRAd-COV2 is a gorilla adenovirus-based COVID-19 vaccine candidate encoding prefusion-stabilized spike. The safety and immunogenicity of GRAd-COV2 is evaluated in a dose- and regimen-finding phase 2 trial (COVITAR study, ClinicalTrials.gov: NCT04791423) whereby 917 eligible participants are randomized to receive a single intramuscular GRAd-COV2 administration followed by placebo, or two vaccine injections, or two doses of placebo, spaced over 3 weeks. Here, we report that GRAd-COV2 is well tolerated and induces robust immune responses after a single immunization; a second administration increases binding and neutralizing antibody titers. Potent, variant of concern (VOC) cross-reactive spike-specific T cell response peaks after the first dose and is characterized by high frequencies of CD8s. T cells maintain immediate effector functions and high proliferative potential over time. Thus, GRAd vector is a valuable platform for genetic vaccine development, especially when robust CD8 response is needed

LE CADUTE ACCIDENTALI NELL\u2019AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA DI VERONA.

Le cadute accidentali del paziente durante la degenza in ospedale rappresentano un indicatore di processo e di esito della qualit\ue0 delle attivit\ue0 assistenziali, ma sono anche un evento sentinella considerato in grado di innescare processi di miglioramento della qualit\ue0 delle cure e favorire un atteggiamento proattivo, attraverso la ricerca delle cause che hanno determinato l\u2019evento. Per com- prendere le dinamiche del fenomeno, nell\u2019Azienda Ospedaliera Universitaria Integrata (AOUI) di Verona \ue8 stata condotta una indagine retrospettiva biennale

Quality of life in patients with Charcot-Marie-Tooth disease

The authors evaluated quality of life in Charcot-Marie-Tooth disease by administering the Medical Outcome Study Short Form-36 (SF-36) questionnaire to 121 Italian patients. Patients scored lower on all of the SF-36 scales compared with Italian normative data. Scores were lower in nonworking vs working patients, women vs men, and older vs younger patients, but not between patients with demyelinating vs axonal forms or between patients who had undergone orthopedic foot surgery vs those who had not